Premium
The central role of the chemokine receptor, CXCR4, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders?
Author(s) -
Watt S. M.,
Forde S. P.
Publication year - 2008
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2007.00995.x
Subject(s) - cxcr4 , chemokine receptor , transplantation , immunology , stem cell , medicine , hematopoietic stem cell transplantation , chemokine , biology , inflammation , microbiology and biotechnology
Recent clinical trials have used CXCR4 antagonists for the rapid mobilization of CD34 + haemopoietic stem/progenitor cells (HSC/HPC) from the bone marrow to the blood in patients refractory to granulocyte–colony‐stimulating factor (G‐CSF). These antagonists not only mobilize non‐cycling cells with a higher proportion of repopulating cells, but also enhance CD34 + cell mobilization when used in combination with G‐CSF. Here, we review the importance of CXCR4 and its ligand CXCL12 in haemopoiesis, and the potential roles of CXCR4 antagonists in the clinical HSC transplant setting.